

REMARKS

A corrected ADS is provided herewith.

Claims 1-17, 23, 24, and 26 are pending. Claims 18-22 and 25 are withdrawn. The specification is objected to because of the lack of sequence identifiers for the sequences in Figure 1A and 1B. The specification is amended herein to recite the proper sequence identifiers in the Description of the Figures.

Claims 23 and 24 are objected to as being multiple dependent claims depending from another multiple dependent claim. Accordingly, claim 15 has been amended from a dependent claim to an independent claim and claims 23 and 24 now depend from claims 1 and 15.

Claims 1-17, 26, and 27 are rejected under 35 U.S.C § 101 as directed to non-statutory subject matters as the claimed antibodies and polypeptides encompass naturally occurring compositions. Applicant herein amends these claims to recite that the claimed antibodies and polypeptides are isolated. Support for this amendment is found in the specification, for example, at paragraph 88. Accordingly, Applicant respectfully requests reconsideration and withdrawal of this rejection.

Conclusion

Applicant believes all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicant invites the Examiner to contact the undersigned attorney.

No fees are believed due. However, if any fees are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 161445.

Respectfully submitted,

Date: December 24, 2009

/Deborah A. Martin/
Deborah A. Martin, Ph.D.
Attorney For Applicants
Registration No. 44,222

Pfizer Inc.
Legal Division - Patent Department
10555 Science Center Drive
San Diego, CA 92121
Phone: (650) 615-7375
Fax: (650) 615-7501
Email: deborah.a.martin@pfizer.com